UCF Nanoparticle Offers Promise for Treating GlaucomaJune 19, 2007A unique nanoparticle made in a laboratory at the University of Central Florida is proving promising as a drug delivery device for treating glaucoma, an eye disease that can cause blindness and affects millions of people worldwide. "The nanoparticle can safely get past the blood-brain barrier making it an effective non-toxic tool for drug delivery," said Sudipta Seal, an engineering professor with appointments in UCF's Advanced Materials Processing and Analysis Center and the Nanoscience Technology Center. The findings will be published in an article appearing in the June 28 issue of the Journal of Physical Chemistry C.
Seal and his colleagues from North Dakota State University note in the article that while barely 1-3 percent of existing glaucoma medicines penetrate into the eye, earlier experiments with nanoparticles have shown not only high penetration rates but also little patient discomfort. The miniscule size of the nanoparticles makes them less abrasive than some of the complex polymers now used in most eye drops. Seal and his team created a specialized cerium oxide nanoparticle and bound it with a compound that has been shown to block the activity of an enzyme (hCAII) believed to play a central role in causing glaucoma. The disease involves abnormally high pressure of the fluid inside the eye, which, if left untreated, can result in damage to the optic nerve and vision loss. High pressure occurs, in part, because of a buildup of carbon dioxide inside the eye, and the compound blocks the enzyme that produces carbon dioxide. Seal and a team of collaborators including Sanku Mallik, of North Dakota State University, developed the research on using nanoparticles as a delivery mechanism for the compound after supervising a student summer project at UCF. Duke University undergraduate Serge Reshetnikov spent a summer studying nanoscience on UCF's Orlando campus as part of a Research Experience for Undergraduates (REU) project funded by the National Science Foundation. Reshetnikov started looking into the possibilities of using nanoparticles as drug delivery tools. Subsequent research with his advisors led to the specific application for glaucoma. In their paper on the research, which was also supported by the National Science Foundation, Seal and Mallik note the results are "very promising" and that their nanoparticle configuration offers seemingly limitless possibilities as a non-toxic drug delivery tool. University of Central Florida | |||||||||||||||||||||
|
Related Glaucoma Current Events and Glaucoma News Articles Melatonin may save eyesight in inflammatory disease Current research suggests that melatonin therapy may help treat uveitis, a common inflammatory eye disease. The related report by Sande et al., "Therapeutic Effect of Melatonin in Experimental Uveitis," appears in the December issue of The American Journal of Pathology. Eye conditions linked with obstructive sleep apnea If a good night's sleep helps the brain and body perform better, it's a good guess that sleep problems can cause more than just fatigue. Numerous studies have shown a connection between sleep disorders and medical conditions such as cardiovascular disease, cerebrovascular disease, and metabolic disorders, including the risk of obesity and diabetes mellitus. In the November issue of Mayo Clinic Proceedings, Mayo Clinic researchers outline several interesting associations between sleep disorders and eye disease. Vision loss more common in people with diabetes Visual impairment appears to be more common in people with diabetes than in those without the disease, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Medication slows progression of myopia in children Daily treatment with a medication called pirenzepine can slow the rate of progressive myopia, or nearsightedness, in children, reports a study in the August issue of the Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus). Glaucoma procedure now available at Mayo Clinic aims to prevent further eye damage For the first time in Florida, patients with glaucoma have a new treatment option known as the Trabectome. Case Western Reserve and Penn State investigators inhibit corneal inflammation Researchers from the Case Western Reserve University School of Medicine and Penn State Hershey College of Medicine identified a novel therapeutic that reduces sterile inflammation within the cornea. Glaucoma report points to increased costs A new Centre for Eye Research Australia/ Access Economics report shows the cost of glaucoma will more than double in the next two decades. 'Fluorescent' cells give early warning for eye disease Scientists at the University of Michigan have shown that their new metabolic imaging instrument can accurately detect eye disease at a very early stage. Role identified for glaucoma gene and related signaling pathway Researchers have found that a gene and a related signaling pathway play a role in the development of glaucoma, which is a common cause of visual impairment and blindness worldwide. Cost of glaucoma medications may impact treatment In the United States, the management of glaucoma costs about $2.5 billion per year. Of the $1.9 billion in direct costs, glaucoma medications account for an estimated 38% to 52% of the total. More Glaucoma Current Events and Glaucoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||